CPHARM - CRC Study
Community Pharmacy-Based Health-Seeking Behaviour and Colorectal Cancer Screening Uptake Among Malaysian Adults
Colorectal cancer is one of the most common cancers in Malaysia and worldwide. Although it can often be prevented or treated successfully when detected early, many people in Malaysia are diagnosed at an advanced stage. Screening tests, such as the immunochemical faecal occult blood test (iFOBT), can help detect early signs of colorectal cancer; however, participation in screening remains low.
Community pharmacies are easily accessible healthcare settings where people frequently seek health advice. Pharmacists may play an important role in improving awareness and encouraging colorectal cancer screening by providing education and support. However, more information is needed to understand how people perceive and respond to pharmacy-based colorectal cancer screening.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Geschat)
Fase
- Niet toepasbaar
Contacten en locaties
Studiecontact
- Naam: Yen Jun Wong
- Telefoonnummer: 60355146286
- E-mail: yenjun.wong@monash.edu
Studie Contact Back-up
- Naam: Chee Tao Chang
- E-mail: davidcct.crc@gmail.com
Studie Locaties
-
-
Selangor
-
Klang, Selangor, Maleisië, 41050
- Big Caring Group
-
Contact:
- Shiau Hueh Yeow
- Telefoonnummer: 60374531988
- E-mail: shiauhueh.yeow@bigcaring.com.my
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Beschrijving
Inclusion Criteria:
- Adults aged 50 to 75 years
- Visiting participating community pharmacies during the study period
- Able to provide informed consent
- Willing to complete the study questionnaire
- Willing to provide consent for follow-up assessment of: iFOBT provision, iFOBT testing completion, iFOBT results
Exclusion Criteria:
- Previous diagnosis of colorectal cancer
- History of colonoscopy within the recommended screening interval (within past 1 year)
- Currently experiencing symptoms suggestive of colorectal cancer
- Having a first-degree relative diagnosed with colorectal cancer
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Onderzoek naar gezondheidsdiensten
- Toewijzing: Niet-gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Pharmacy customers with campaign
Campaign Components The one-day Ribbon of Hope campaign will be implemented at each intervention pharmacy to promote colorectal cancer awareness and screening uptake.
The campaign consists of educational materials and one-on-one education about colorectal cancer.
|
Campaign Components The one-day Ribbon of Hope campaign will be implemented at each intervention pharmacy to promote colorectal cancer awareness and screening uptake.
The campaign consists of educational materials and one-on-one education about colorectal cancer.
|
|
Geen tussenkomst: Pharmacy customers without campaign
Customers will receive standard pharmacy services such as medication dispensing and general health advice, but no educational materials or one-on-one education on CRC will be provided.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Beliefs and perceptions toward colorectal cancer and iFOBT screening
Tijdsspanne: From enrollment to the 8th week follow-up.
|
Beliefs and perceptions toward colorectal cancer and iFOBT screening, measured using the Champion Health Belief Model Scale - Colorectal Cancer - Malay (CHBMS-CRC-M) subscales of perceived susceptibility, perceived benefits, and perceived barriers, between customers from pharmacies with and without the one-day awareness campaign. Each item is rated on a 5-point Likert scale (1 = strongly disagree to 5 = strongly agree). Domain scores will be calculated by summing (or averaging) the items within each domain, with higher scores indicating greater perceived susceptibility, benefits or barriers. |
From enrollment to the 8th week follow-up.
|
Secundaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
|---|---|
|
Proportion of participants who were willing to accept and perform iFOBT, report iFOBT results, and follow-up if needed.
Tijdsspanne: From enrollment to the 8th week of follow-up
|
From enrollment to the 8th week of follow-up
|
Medewerkers en onderzoekers
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 53176
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .